Genomic landscape of acquired resistance to targeted therapies in metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Harrold, Emily
Keane, Fergus
Sinopoli, Jenna Cohen
Diaz, Luis A.
Cercek, Andrea
Yaeger, Rona
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, GME Off, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
190
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [41] Novel somatic genetic variants as predictors of resistance to EGFR-targeted therapies in metastatic colorectal cancer patients
    Riera, P.
    Rodriguez-Santiago, B.
    Lasa, A.
    Gonzalez-Quereda, L.
    Martin, B.
    Salazar, J.
    Sebio Garcia, A.
    Virgili Manrique, A. C.
    Surralles, J.
    Paez, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S434 - S434
  • [42] Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients
    Riera, Pau
    Rodriguez-Santiago, Benjamin
    Lasa, Adriana
    Gonzalez-Quereda, Lidia
    Martin, Berta
    Salazar, Juliana
    Sebio, Ana
    Virgili, Anna C.
    Minguillon, Jordi
    Camps, Cristina
    Surralles, Jordi
    Paez, David
    CANCERS, 2020, 12 (08) : 1 - 15
  • [43] Understanding the Genomic Landscape of Glioblastoma: Opportunities for Targeted Therapies
    Zeller, Sabrina l.
    Spirollari, Eris
    Chandy, Anisha m.
    Hanft, Simon j.
    Gandhi, Chirag d.
    Jhanwar-Uniyal, Meena
    ANTICANCER RESEARCH, 2024, 44 (11) : 4677 - 4690
  • [44] Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC)
    Yeh, Celine
    Harrold, Emily
    Keane, Fergus
    Sinopoli, Jenna Cohen
    Foote, Michael Bonner
    Cercek, Andrea
    Yaeger, Rona
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
    Steven M. Bray
    Jeeyun Lee
    Seung Tae Kim
    Joon Young Hur
    Philip J. Ebert
    John N. Calley
    Isabella H. Wulur
    Thejaswini Gopalappa
    Swee Seong Wong
    Hui-Rong Qian
    Jason C. Ting
    Jiangang Liu
    Melinda D. Willard
    Ruslan D. Novosiadly
    Young Suk Park
    Joon Oh Park
    Ho Yeong Lim
    Won Ki Kang
    Amit Aggarwal
    Hee Cheol Kim
    Christoph Reinhard
    Scientific Reports, 9
  • [46] Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
    Bray, Steven M.
    Lee, Jeeyun
    Kim, Seung Tae
    Hur, Joon Young
    Ebert, Philip J.
    Calley, John N.
    Wulur, Isabella H.
    Gopalappa, Thejaswini
    Wong, Swee Seong
    Qian, Hui-Rong
    Ting, Jason C.
    Liu, Jiangang
    Willard, Melinda D.
    Novosiadly, Ruslan D.
    Park, Young Suk
    Park, Joon Oh
    Lim, Ho Yeong
    Kang, Won Ki
    Aggarwal, Amit
    Kim, Hee Cheol
    Reinhard, Christoph
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [47] Current management of metastatic colorectal cancer - the evolving impact of targeted drug therapies
    Yau, T.
    Chan, P.
    Chan, Y. Ching
    Wong, B. C. Y.
    Liang, R.
    Epstein, R. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (11) : 997 - 1005
  • [48] The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer
    Fakih, Marwan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (04) : 427 - 438
  • [49] OPINION More is less-combining targeted therapies in metastatic colorectal cancer
    Punt, Cornelis J. A.
    Tol, Jolien
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (12) : 731 - 733
  • [50] Front-line use of FOLFOXIRI plus bevacizumab and subsequent therapies in metastatic colorectal cancer (mCRC).
    Barzi, Afsaneh
    Lunacsek, Orsolya
    Pisa, Federica
    Pan, Xiaoyun
    Ostojic, Helene
    Vassilev, Zdravko
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 45 - 45
12345